CurrentRheuma
Get Weekly

Topic · page 10 of 17

Systemic sclerosis & Raynaud's

Limited and diffuse systemic sclerosis, skin, lung (interstitial lung disease), pulmonary arterial hypertension, heart, gut and kidney involvement in systemic sclerosis, digital ulcers, primary and secondary Raynaud's phenomenon, very early systemic sclerosis

Briefs 361–400 of 671 placed here, newest publication first

Briefs in Systemic sclerosis & Raynaud's

Newest publication first

  1. Rheumatology (Oxford)

    The 2024 British Society for Rheumatology guideline for management of systemic sclerosis

    Guideline or statement

  2. Clin Exp Rheumatol

    Thymic stromal lymphopoietin in systemic sclerosis interstitial lung disease: a pilot study

    Cross-sectional study

  3. Arthritis Care Res (Hoboken)

    Evaluating the Associations Among Dysautonomia, Gastrointestinal Transit, and Clinical Phenotype in Patients With Systemic Sclerosis

    Cohort study

  4. Rheumatology (Oxford)

    Gastrointestinal dysmotility is associated with proton pump inhibitor refractory oesophagitis in patients with systemic sclerosis

    Cross-sectional study

  5. RMD Open

    Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease

    Secondary analysis

  6. Rheumatology (Oxford)

    Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis

    Cohort study

  7. Clin Exp Rheumatol

    Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study

    Cohort study

  8. Lancet Rheumatol

    The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study

    Cohort study

  9. Ann Rheum Dis

    Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis

    Mechanistic study

  10. Ann Rheum Dis

    Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)

    Diagnostic or prognostic study

  11. Arthritis Care Res (Hoboken)

    Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient‐Reported Outcomes Measurement Information System‐29 Profile Version 2.0 Domains, and Patient Health Questionnaire‐8 in People With Systemic Sclerosis: A Scleroderma Patient‐Centered Intervention Network Cohort Cross‐Sectional Study

    Cross-sectional study

  12. Arthritis Rheumatol

    Toll‐Like Receptor 8 is Expressed in Monocytes in Contrast to Plasmacytoid Dendritic Cells and Mediates Aberrant Interleukin‐10 Responses in Patients With Systemic Sclerosis

    Mechanistic study

  13. Arthritis Rheumatol

    Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index

    Diagnostic or prognostic study

  14. Pediatr Rheumatol Online J

    Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review

    Research article

  15. RMD Open

    Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study

    Cohort study

  16. Rheumatology (Oxford)

    Evaluation of changes in cardiac longitudinal strain rate in patients with systemic sclerosis undergoing iloprost treatment: an observational study

    Cohort study

  17. Clin Exp Rheumatol

    Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)

    Cross-sectional study

  18. Clin Exp Rheumatol

    Gastrointestinal disorders in systemic sclerosis: cluster analysis and prognosis from a French prospective cohort

    Cohort study

  19. Clin Exp Rheumatol

    A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

    Trial design

  20. Clin Exp Rheumatol

    The burden and determinants of fatigue in incident and prevalent systemic sclerosis

    Cohort study

  21. Rheumatology (Oxford)

    Muscle involvement in systemic sclerosis: high mortality not associated with nature of histological lesions

    Cohort study

  22. Rheumatology (Oxford)

    Systemic sclerosis and cancer in the UK: an epidemiological analysis using the clinical practice research datalink

    Cohort study

  23. Clin Exp Rheumatol

    Frailty assessment in patients with systemic sclerosis

    Cross-sectional study

  24. Clin Exp Rheumatol

    Neutrophil gelatinase-associated lipocalin levels are associated with skin thickness and metabolic syndrome features in patients with systemic sclerosis

    Cross-sectional study

  25. Rheumatology (Oxford)

    Racial and ethnic associations with interstitial lung disease and healthcare utilization in patients with systemic sclerosis

    Cohort study

  26. Clin Exp Rheumatol

    Fibroblast activities are associated with prolonged QTc and pulmonary arterial hypertension in patients with systemic sclerosis

    Cross-sectional study

  27. Arthritis Rheumatol

    ERG Regulates Lymphatic Vessel Specification Genes and Its Deficiency Impairs Wound Healing‐Associated Lymphangiogenesis

    Mechanistic study

  28. Clin Exp Rheumatol

    Tumour necrosis factor-like weak inducer of apoptosis participates in the development of cutaneous fibrosis in an experimental systemic sclerosis model

    Mechanistic study

  29. Rheumatology (Oxford)

    Changes of cerebral structure and perfusion in subtypes of systemic sclerosis: a brain magnetic resonance imaging study

    Cross-sectional study

  30. Clin Exp Rheumatol

    The burden of illness of the organ manifestations of systemic sclerosis: a pragmatic, targeted review

    Research article

  31. Clin Exp Rheumatol

    Investigating the trajectory of functional disability in systemic sclerosis: group-based trajectory modelling of the Health Assessment Questionnaire-Disability Index

    Cohort study

  32. Clin Exp Rheumatol

    Comparison of serum exosome miRNA from patients with Raynaud's phenomenon with positive and negative serum antinuclear antibodies

    Cross-sectional study

  33. Arthritis Res Ther

    Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog

    Mechanistic study

  34. Clin Exp Rheumatol

    Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors

    Case-control study

  35. RMD Open

    Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?

    Cohort study

  36. Rheumatology (Oxford)

    Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis

    Cohort study

  37. Rheumatology (Oxford)

    Development of a measuring app for systemic sclerosis-related digital ulceration (SALVE: Scleroderma App for Lesion VErification)

    Research article

  38. Semin Arthritis Rheum

    Clinically relevant differences between primary Raynaud's phenomenon and secondary to connective tissue disease

    Cross-sectional study

  39. Arthritis Res Ther

    Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

    Randomized controlled trial

  40. Rheumatology (Oxford)

    Do functionality, strength, vascularization, inflammatory and biopsychosocial status improve by biopsychosocial model-based exercise in SSc?

    Research article

All 671 Briefs in ExploreShowing Briefs 361–400 of 671, newest first